Acuta Capital Partners LLC Sells 101,330 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Acuta Capital Partners LLC lowered its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 25.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 296,368 shares of the company's stock after selling 101,330 shares during the quarter. Enliven Therapeutics makes up approximately 6.1% of Acuta Capital Partners LLC's portfolio, making the stock its 5th biggest position. Acuta Capital Partners LLC owned approximately 0.63% of Enliven Therapeutics worth $7,569,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of ELVN. FMR LLC raised its position in Enliven Therapeutics by 10.6% in the 3rd quarter. FMR LLC now owns 6,296,179 shares of the company's stock valued at $160,804,000 after purchasing an additional 601,611 shares during the last quarter. First Turn Management LLC acquired a new stake in shares of Enliven Therapeutics during the second quarter worth about $9,657,000. Janus Henderson Group PLC grew its holdings in shares of Enliven Therapeutics by 74.8% during the first quarter. Janus Henderson Group PLC now owns 713,911 shares of the company's stock worth $12,604,000 after buying an additional 305,397 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Enliven Therapeutics during the second quarter worth about $4,489,000. Finally, Nicholas Investment Partners LP acquired a new position in Enliven Therapeutics in the 2nd quarter valued at about $1,310,000. 95.08% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Enliven Therapeutics

In related news, insider Joseph P. Lyssikatos sold 37,878 shares of the firm's stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $28.16, for a total value of $1,066,644.48. Following the completion of the transaction, the insider now directly owns 1,016,035 shares of the company's stock, valued at $28,611,545.60. This trade represents a 3.59 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Samuel Kintz sold 12,206 shares of the business's stock in a transaction on Friday, October 4th. The stock was sold at an average price of $27.51, for a total value of $335,787.06. Following the sale, the chief executive officer now owns 1,036,523 shares in the company, valued at approximately $28,514,747.73. The trade was a 1.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 123,945 shares of company stock worth $3,451,099 over the last three months. 29.20% of the stock is currently owned by corporate insiders.

Enliven Therapeutics Stock Performance

ELVN traded up $1.06 during trading on Thursday, reaching $25.41. The company's stock had a trading volume of 168,715 shares, compared to its average volume of 258,328. The company's fifty day moving average price is $26.71 and its 200-day moving average price is $24.12. Enliven Therapeutics, Inc. has a 52-week low of $9.80 and a 52-week high of $30.03. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -13.37 and a beta of 1.08.

Analysts Set New Price Targets

Several research analysts have weighed in on ELVN shares. HC Wainwright reiterated a "buy" rating and issued a $37.00 target price on shares of Enliven Therapeutics in a research note on Tuesday, October 1st. Robert W. Baird lifted their price objective on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the company an "outperform" rating in a research report on Friday, November 15th.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.